project brijesh singh
DESCRIPTION
mba reserchTRANSCRIPT
-
5/26/2018 Project Brijesh Singh
1/133
PART-I
1
-
5/26/2018 Project Brijesh Singh
2/133
COMPANY PROFILE
2
-
5/26/2018 Project Brijesh Singh
3/133
COMPANY PROFILE
HISTORY OF CIPLA
Cipla is the 2nd largest pharmaceutical company in India in terms of retail
sales. Cipla manufactures an extensive range of pharmaceutical &personal
care products and has presence in over 170 countries across the world.
Ciplas product range include harmaceuticals! and animal "ealth care products
#$C! %ul 'rugs, (lavours and )grochemicals Cipla also provides a host of
consulting service such as preparation of products and material specifications!
evaluation of existing production facilities to meet *+! definition of appropriate
plant si,e and technologies etc.
$he origins of Cipla can -e traced -ac to 1/! when 'r hwaa )-dul "amied set
up 3$he Chemical! Industrial and harmaceutical 4a-oratories 4td3! popularly nown
-y the acronym Cipla! in a rented -ungalow! at %om-ay Central. Cipla was registered
as a pu-lic limited company on )ugust 17! 1/. Cipla5s first product was launched
into the maret in 1/7. In 160! during the econd 8orld 8ar when the drug
supplies were cut off! Cipla started producing fine chemicals. In 166! Cipla -ought
the premises at %om-ay Central to -uild a modern pharmaceutical la-oratory. In
169! Cipla5s product for hypertension! erpinoid! was exported to the )merican
:oland Corporation. In 12! Cipla set up first research division for attaining self;
sufficiency in technological development. In 190! Cipla started operations at second
plant at
-
5/26/2018 Project Brijesh Singh
4/133
In 1=2! Cipla5s fourth factory -ecame operational at atalganga! +aharashtra. In
1=6! Cipla developed anti;cancer drugs! vin-lastine and vincristine in colla-oration
with the >ational Chemical 4a-oratory! une. In 11! Cipla pioneered the
manufacture of the antiretroviral drug! ,idovudine.
In 16! Cipla5s fifth factory -egan commercial production at urum-h!
+aharashtra. In 17! Cipla launched transparent :otahaler! the world5s first such dry
powder inhaler device. In 2000! Cipla -ecame the first company! outside the ?) and
@urope to launch C(C;free inhalers. In 2002! Cipla *oa.
In set up four state;of;the;art manufacturing facilities set up in 200/! Cipla launched
$I#
-
5/26/2018 Project Brijesh Singh
5/133
-irth of the Council of cientific and Industrial :esearch ACI:B! which is today the
apex research -ody in the country.
'r. Dusuf . "amied is a gifted entrepreneur of the Indian pharmaceutical
industry. )part from -eing an accomplished scientist! he com-ines great
-usiness acumen and intellect to strie the right -alance -etween -usiness
considerations and social and humanitarian goals. "e is currently the Chairman
and +anaging 'irector of Cipla 4imited! which is renowned -oth locally and
internationally for its high standards! Euality! efficacy and afforda-ility of
medicines.
%orn on 2 th uly 1/9 ! 'r. "amied o-tained h.' in #rganic Chemistry
from Cam-ridge ?niversity. In the same year! he oined Cipla as a :esearch
#fficer. "e was appointed as its +anaging 'irector in 179 and Chairman in
the year 1=.
'r. "amied has -een primarily responsi-le in the introduction! for the first
time in India! of over /0 -ul drugs and their formulations. "e is considered a
pioneer of -ul drug industry in India and has a num-er of research papers and
international patents to his credit. (rom a hum-le -eginning! Cipla under the
guidance of 'r. "amied is now raned as a leader in the domestic
pharmaceutical industry. $he company5s turnover in 2006;200 has exceeded
:s. 2/00 crores of which 60F is exports. Cipla today manufactures and
marets a wide range of medicines not only for the local maret -ut also for
export to 10 countries worldwide.
'r. "amied has pioneered and led the glo-al fight against "I< and )I'.
Cipla was the first to offer the triple drug coctail! $riomune! that can
-
5/26/2018 Project Brijesh Singh
6/133
transform the life of an "I< positive patient at a fraction of the international
cost. "e had -een instrumental in setting up a palliative care for cancer patients
in une during the 105s. $his centre follows a uniEue family care modal!
which offers free of cost! comfort and care to terminally ill cancer patients.
$he recognitions received -y Cipla under the leadership of 'r. D. . "amied
include two Chemexcil )wards for exports A17 and 1=2B! ir . C. :ay
)ward for development of indigenous technology A1=/B and a >ational )ward
from the 'epartment of cience and $echnology! *overnment of India for
successful commerciali,ation of pu-licly funded : & ' was conferred on 'r.
"amied. In 2002! he received another 4ifetime )chievement award from
@xpress harma ulse. 'r. "amied was elected a (ellow of Christ5s College!
Cam-ridge! ? in 2006.
CIPLA IN NEWS-:
9
-
5/26/2018 Project Brijesh Singh
7/133
/0 )pril!
200=
20 +arch!
200=
01 anuary!
200=
2=
>ovem-er!
2007
0 #cto-er!
2007
06
eptem-er!
2007
01
eptem-er!
2007
2= )ugust!
2007
2= )ugust!
2007
2 )ugust!
200722 )ugust!
2007
21 )ugust!
2007
7
CiplaG #verseas sales a -ooster
Cipla scores a generic win over :oche
Cipla maintains >o.1 position in Indian mt
)ward for the (or-es )sia5s H%est ?nder ) %illion 4istJ
17 Indian firms in (or-es5 list of top )sian cos -elow K1 -n
Indian pharma industry L Coming out of the shadows
)nti;)I' -lit, sees pharma firms loced in ugly -attle
Ciplas drug included in ? anti;)I' initiative
Cipla to replace all products with C(C ahead of deadline
Cipla plans :s 0;cr capacity expansion
Cipla notice to ? >*# on )I' drug
Cipla launches emergency contraception ta-let
Cipla in tals with $hai govt for "I< drugs supply
(irst fixed;dose! triple com-ination paediatric )I' drug approved under @():
Aresident5s @mergency rogram for )I' :eliefB
)I' drug not sold in )frica! says Cipla
Ciplas response to the advertisement issued -y )I' "@)4$"C):@ (#?>')$I#>
on )ugust ! 2007 in various newspapers
Cipla edges :an-axy in India maret
Cipla launches estradiol transdermal spray in India
$he presence of Indian generic manufacturers in the ):< segment of low and middle
income countries
Cipla ; organic growth and alliances pave the way for new products
India5s Cipla in tals to )lly with *eneric companies in apan
Cipla launches cut;price ,anamivir in India
Cipla receives International $rade )wards 2009 for outstanding exporter of the year.
Cipla launches anti;malaria glo-al initiative
-
5/26/2018 Project Brijesh Singh
8/133
CIPLAS PRODUCT INCLUDES
Pharmaceutca!"G Cipla manufactures ana-olic steroids! analgesicsMantipyretics!
antacids! anthelmintics! anti;arthritis! anti;inflammatory drugs! anti;$% drugs! ant
allergic drugs! anticancer drugs! antifungal! antimalarials! antispasmodics!
antiulcerants! immunosuppressants etc.
A#ma! Hea!th Care Pr$%uct": $hese includeG aEua products! eEuine products!
poultry products! products for companion animals! and products for livestoc
animals.
OTC: $hese includeG child care products! eye care products! food supplements!
health drins! life style products! nutraceuticals & tonics! sin care products! and
oral hygiene products.
F!a&$ur ' Fra(ra#ce: Cipla manufactures a wide range of flavours! which are
used in foods and -everages! fruit uices! -aed goods! and oral hygiene products.
Cipla fragrances have wide ranging applications such as in personal care products!
=
-
5/26/2018 Project Brijesh Singh
9/133
laundry detergents and room fresheners.
MA)OR ACHIE*EMENTS OF CIPLA
+anufactured ampicillin for the first time in India.
4auched etoposide! a -reathrough in cancer chemotherapy! in
association with Indian Institute of Chemical $echnology
4aunches transparent :otahaler! the world5s first such dry powder
inhaler device.
4aunches transparent :otahaler! the world5s first such dry powder inhaler
device.
%ecame the first company! outside the ?) and @urope to launch.
C(C;free inhalers
MILESTONE OF CIPLA
-
5/26/2018 Project Brijesh Singh
10/133
+.
'r ) "amied sets up 3$he Chemical! Industrial and harmaceutical 4a-oratories
4td.3 in a rented -ungalow! at %om-ay Central.
+/+
)s the econd 8orld 8ar cuts off drug supplies! the company starts producing fine
chemicals! dedicating all its facilities for the war effort.
+.0ets up first research division for attaining self;sufficiency in technological
development.
+12
tarts operations at second plant at ational Chemical 4a-oratory! une. 8ins ir C :ay )ward for developing inhouse
technology for indigenous manufacture of a num-er of -asic drugs.10
-
5/26/2018 Project Brijesh Singh
11/133
5LO6AL PRESENCE
@xports for the financial year ended +arch /1! 200= amounted to more than :s.
21!000 million. Cipla exports raw materials! intermediates! prescription drugs!
#$C products and veterinary products. Cipla also offers technology for
products and processes. $echnical now;howMfees received during the year
2007;0= amounted to a-out :s. 100 million.
Cipla5s manufacturing facilities have -een approved -y the following regulatory
authoritiesG
(ood and 'rug )dministration A(')B! ?)
+edicines and "ealthcare products :egulatory )gency A+":)B! ?
$herapeutic *oods )dministration A$*)B! )ustralia
+edicines Control Council A+CCB! outh )frica
>ational Institute of harmacy A>IB! "ungary
haramaceutical Inspection Convention AICB! *ermany
8orld "ealth #rganisation A8"#B 'epartment of "ealth! Canada
tate Institute for the Control of 'rugs! lova :epu-lic )>
-
5/26/2018 Project Brijesh Singh
12/133
C7!a 7r$%uct" are 8$u(ht 89 $&er +42 c$u#tr9 !$cate% # the $!!$;#( re($#"
CODE OF CONDUCT
12
-
5/26/2018 Project Brijesh Singh
13/133
)s reEuired under revised Clause 6 of the 4isting )greement the following code of
conduct has -een approved -y the %oard of 'irectors and is applica-le to the 'irctors
and enior +anagement of the Company.
+< Ethca! c$#%uct
)ll directors and senior management employees shall deal on -ehalf of the Company
with professionalism! honesty! integrity as well as high moral and ethical standards.
uch conduct shall -e fair and transparent and -e perceived to -e as such -y third
parties.
0< C$#!ct $ #tere"t
)ny director or senior management employee of the Company shall not engage in
any -usiness! relationship or activity! which might detrimentally conflict with the
interest of the Company.
< Tra#"7are#c9
)ll directors and senior management employees of the Company shall ensure that
their actions in the conduct of -usiness are totally transparent except where the needs
of -usiness security dictate otherwise. uch transparency shall -e -rought a-out
through appropriate policies! systems and processes.
/< Le(a! c$m7!a#ce
)ll directors and senior management employees of the Company shall at all times
ensure compliance with all the relevant laws and regulations affecting operations of
the Company. $hey shall a-reast of the affairs of the Company and -e ept informed
of the Company5s compliance with relevant laws! rules and regulations. In the event
that the implication of law is not clear! the course of action chosen must -e
supported-y eminent legal counsel whose opinion should -e documented.
.< R(htu! u"e $ c$m7a#9" a""et"
)ll the assets of the Company -oth tangi-le and intangi-le shall -e employed for the
purpose of conducting the -usiness for which they are duly authori,ed. >one of the
assets of the Company should -e misused or diverted for personal purpose.
1< C$"t c$#"c$u"#e""
)ll the directors and senior management employees of the Company should strive for
optimum utili,ation of availa-le resources. $hey shall exercise care to ensure that
1/
-
5/26/2018 Project Brijesh Singh
14/133
COMPANY 5ROWTH STRATE5Y
'evelopment of innovative drug delivery systems for new and existing active drug
su-stances continued to -e an integral part of the Company5s growth strategy.
8or on new medical devices! mainly in the area of respiratory medicine!
progressed rapidly! as did its inhaled insulin proect.$he Company has developed
a uniEue transdermal delivery system. It has already launched a spray patch for
testosterone andanother for estradiol. #ther new developments include a novel
dry powder inhaler device and a uniEue single;action single;dose inhaler device.
Cipla has entered into a research agreement with )vestha *ngraine $echnologies
rivate 4imited! %angalore with the o-ective of woring on a colla-orative
-iopharmaceuticals development programme. $he partnership will focus on the
development of range of -iosimilar products for autoimmune disorders!
cardiovascular diseasesandca.
Dru( Prc#(:-
$he government5s drug pricing policy has a direct -earing on the health of the
domestic pharmaceutical industry. 8e understand that the policy is -eing looed
into -y a *roup of +inisters A*#+B and we hope that! instead of ar-itrary drug
control measures! the *#+ would let free and fair competition determine drug
prices.$his will ena-le all Indians to have access to afforda-le healthcareect&e:
$o find out sales volume of urological drugs vis;N;vis competitor
$o find out doctors who prescri-es competitor product
uggestion for the company from retailers
Sec$#%ar9 O8>ect&e:
$o increase their maret share -y approaching to doctors who prescri-e
competitors product.
$o have a good image in the eyes of retailers.
21
-
5/26/2018 Project Brijesh Singh
22/133
RESEARCH METHODOLO5Y
22
-
5/26/2018 Project Brijesh Singh
23/133
RESEARCH METHODOLO5Y
+< Re"earch Pr$ce""
1.(ormulation of the o-ective of the study of the pro-lem
'esigining method for data data collection.
electing the method si,e.
Collecting the data
:eporting and interpretation the finding
rocessing and analy,ing the data
(ind the conclusion
4imitation of study
Re"earch De"(#; ) Re"earch De"(# is simply the framewor or plan of a study
that is used as guide in collecting and analy,ing the data. It is a -lueprint that is
followed in completing a study.
H) research design is the plan! structure and strategy of investigation conceived so
as to o-tain answers to research Euestions and to control variance.
$he research carried out is a %e"cr7t&e re"earchwhere the purpose is to go through
an intensive study of the target segment.
ample design;I have done my survey in *ha,ia-ad and some of the selected
areas of >oida .
2/
-
5/26/2018 Project Brijesh Singh
24/133
Sam7!e tech#?ue";$he data has -een collected through random sampling from
the retailers of *ha,ia-ad and >oida.
U#&er"e S@e-
$he universe is the entire group of items the researcher wishes to study.
ince my survey was confined to -e done in *ha,ia-ad and >oida. $his universe
si,e having a sample of 120 respondents.
+
-
5/26/2018 Project Brijesh Singh
25/133
L"t $ *"t#( Reta!Me%ca! St$re:
Me%ca! St$re A%%re""
'evil hree +edico
-
5/26/2018 Project Brijesh Singh
26/133
arvodaya "ospital avi >agar
+edicine oint avi >agar
$he Chemist Corner avi >agar
?pchar +edico, avi >agar
*ha,ia-ad +edical avi >agar
raash +edical tore hastri >agar
aneevan +edical tore hastri >agar
upreme +edico, hastri >agar
hivam +edical tore hastri >agar
Dash +edical tore hastri >agar
Dash +edical tore hastri >agar
:adhia +edical tore hastri >agar
%havana +edical anay >agar ec2/
hivam "ospital :a >agar
+arigold Chemist :'C :anagar
*uardian harmacy :'C :anagar
rishna +edico, :'C :anagar
%alai +edical anay >agar ec2/
hyam "ospital ec. :a >agar
*argi "ospital ec. :a >agar
ai %havani +edical *andhi >agar
uper +edical tore *andhi >agar
+ehta +edical *andhi >agar
"arsh +edical *andhi >agar
%hagwati +edical *andhi >agar
29
-
5/26/2018 Project Brijesh Singh
27/133
>eE )m-e +edical *andhi >agar
Dashoda "ospital >ehru >agar
8adhwa +edical >ehru >agar
?ttam +edical >ehru >agar
)grawal +edical tore #ld %us tand
+ehra ons #ld %us tand
>agar +edicine tore #ld %us tand
hu-h +edical tore #ld %us tand
)rihant +edical tore #ld %us tand
ona +edical tore anay Colony +ohan >agar
*anesh +edical tore anay Colony +ohan >agar
'atta +edical tore )rthala +ohan >agar
4axmi +edical tore )rthala +ohan >agar
)mit +edical tore )rthala +ohan >agar
)nanad +edical tore )rthala +ohan >agar
>arinder +ohan "ospital )rthala +ohan >agar
)m-e "ospital :aendra >agar hahi-a-ad
+.. +edical :aendra >agar hahi-a-ad
%rother +edical :aendra >agar hahi-a-ad
hree i +edico, :aendra >agar hahi-a-ad
eg +edico, :aendra >agar hahi-a-ad
amal +edical :aendra >agar hahi-a-ad
ratap +edical 4apat >agar hahi-a-ad
Dugal +edical 4apat >agar hahi-a-ad
erfect +edical 4apat >agar hahi-a-ad
27
-
5/26/2018 Project Brijesh Singh
28/133
$ina +edico, 4apat >agar hahi-a-ad
:.). +edico, 4apat >agar hahi-a-ad
)m-a +edical 4apat >agar hahi-a-ad
>ew "ind +edical hyam ar hahi-a-ad
>aamdhari +edical hyam ar hahi-a-ad
agar ec2/
4alit +edical anay >agar ec2/
Chaudhari +edical anay >agar ec2/
artiey +edical anay >agar ec2/
aneev medical anay >agar ec2/
?ttam +edical >ehru >agar
?ttam "ospital agar
hivali +edical tore agar
hishodiya +edical tore agar
rishna +edical tore agar
%havana +edical tore ratap
-
5/26/2018 Project Brijesh Singh
29/133
ear +etro "ospital >oida
aaras +edical tore >ear +etro "ospital >oida
*uardaian harmacy oida
raash "ospital ec/2 >oida
"oney +edico, ec/ >ear ura-hi "ospital
*a"hu#%har
a
Pate!
Na(ar
Ma!;ara
Ch$;= =aa(ar
Sha"tr
Na(ar
O!% 6u"
Sta#%
M$ha
#
Na(ar Shaha8a8a%
Ra>
Na(ar
5a#%h
Na(ar
Nehru
Na(ar
*>a9
Na(ar
Prata7
*har
M$%
Na(ar
42 1 +1/ +. +3 . /3 10 1 ++ .+ +2 +2 ./
2
-
5/26/2018 Project Brijesh Singh
30/133
6ar chart "h$;#( the "a!e" $ UrmaB # &ar$u" re($# $ 5ha@a8a%
UrmaB *e!tam Tam!$;
C$#t!$
; Tamc$#t# D9#a 7re""
++ /4 +. +3 4
/0
-
5/26/2018 Project Brijesh Singh
31/133
Pe chart "h$;#( the "a!e" $ urmaB # # 5a#%h #a(ar area $ &"--&" t"
c$m7ett$r
UrmaB Ur"7a"+. .
/1
-
5/26/2018 Project Brijesh Singh
32/133
Pe chart "h$;#( the "a!e" $ UrmaB # =a& #a(ar # 5ha@a8a% &"--&" t"
c$m7ett$r
UrmaB
D9#a
7re"" Ur"7a"
+1/ 3. +2
Pe chart "h$;#( the "a!e" $ UrmaB # Ma!;ara Ch$;= area $ 5ha@a8a% &"--
&" t"
C$m7ett$r
/2
-
5/26/2018 Project Brijesh Singh
33/133
UrmaB *e!tam Tam!$;
C$#t!$
; Tamc$#t#
D9#a
7re""
./ +1 2 2 2 2
//
-
5/26/2018 Project Brijesh Singh
34/133
Pe chart "h$;#( the "a!e" $ UrmaB # m$%#a(ar area $ 5ha@a8a% &"--&" t"
c$m7ett$r
/6
-
5/26/2018 Project Brijesh Singh
35/133
UrmaB Ur"7a"
/3 /
Pie chart "h$;#( the "a!e" $ UrmaB # M$ha# #a(ar area $ 5ha@a8a% &"-a&"
t" c$m7ett$r
/
-
5/26/2018 Project Brijesh Singh
36/133
UrmaB *e!tam Tam!$;
C$#t!$
; Tamc$#t#
D9#a
7re""
/+ +4 03 2
/9
-
5/26/2018 Project Brijesh Singh
37/133
7e chart "h$;#( the "a!e" $ UrmaB # Nehru #a(ar area $ 5ha@a8a% &"--&" t"
c$m7ett$r
/7
-
5/26/2018 Project Brijesh Singh
38/133
UrmaB Other". 2
O
Pe chart "h$;#( the "a!e" $ UrmaB # O!% 8u" "ta#% area $ 5ha@a8a% &"--&" t"
c$m7ett$r
/=
-
5/26/2018 Project Brijesh Singh
39/133
UrmaB Other"
1 2
/
-
5/26/2018 Project Brijesh Singh
40/133
Pe chart "h$;#( the "a!e" $ UrmaB # Pate! #a(ar area $ 5ha@a8a% &"--&" t"
c$m7ett$r
60
-
5/26/2018 Project Brijesh Singh
41/133
UrmaB *e!tam10 +4
Pe chart "h$;#( the "a!e" $ UrmaB # ra> #a(ar area $ 5ha@a8a% &"--&" t" c$m7ett$r
61
-
5/26/2018 Project Brijesh Singh
42/133
UrmaB *e!tam Tam!$; C$#t!$; Tamc$#t# D9#a 7re""
+2 2 2 +2 2 2
10
62
-
5/26/2018 Project Brijesh Singh
43/133
Pe chart "h$;#( the "a!e" $ UrmaB # Prata7 &har area $ 5ha@a8a% &"--&" t"
C$m7ett$r
6/
-
5/26/2018 Project Brijesh Singh
44/133
UrmaB *e!tam
10 ++
Pe chart "h$;#( the "a!e" $ UrmaB # Shah8a8a% area $ (ha@a8% &"--&" t"
c$m7ett$r
66
-
5/26/2018 Project Brijesh Singh
45/133
UrmaB Other"
+3 2
6
-
5/26/2018 Project Brijesh Singh
46/133
Pe chart "h$;#( the "a!e" $ UrmaB # Sha"tr #a(ar $ 5ha@a8a% &"--&" t"
c$m7ett$r
69
-
5/26/2018 Project Brijesh Singh
47/133
UrmaB Ur"$! F!$%art
42 +. .
Pe chart "h$;#( the "a!e" $ urmaB # &a"hu#%hara area $ 5ha@a8a% &"-a -&" t"
c$m7ett$r
67
-
5/26/2018 Project Brijesh Singh
48/133
UrmaB *e!tam Tam!$;
C$#t!$
; Tamc$#t#
D9#a
7re""
+2 2 2 2 2 2
6=
-
5/26/2018 Project Brijesh Singh
49/133
Pe chart"h$;#( the "a!e" $ UrmaB # &>a9 #a(ar area $ 5ha@a8a% &"--&" t"
c$m7ett$r
6
-
5/26/2018 Project Brijesh Singh
50/133
Ur
maB *e!tam
D9#a
7re""
Tam
!$; Tamc$#t#
C$#t
!$; F!$%art Ur"$! Ur"7a"
143 +23 ++3 +3 +2 .1 . +. +
Pe chart "h$;#( the "a!e" $ urmaB &"--&" t" c$m7ett$r # 5ha@a8a%
0
-
5/26/2018 Project Brijesh Singh
51/133
*a"hu#%hara
Pate!
#a(ar
Ma!;ara
ch$;=
a&
#a(ar
Sha"tr
#a(ar
O!% 8u"
"ta#%
M$ha#
Na(ar Shah8a8a%
Ra>
#a(ar
5a#%h
#a(ar
Nehru
#a(ar
*>a9
#a(ar
Prata7
&har
M$%
#a(ar
0 0 +. 1 / 2 2 / 01 1 4 + . +.
1
-
5/26/2018 Project Brijesh Singh
52/133
6ar chart "h$;#( the "a!e" $ UrmaB-D # &ar$u" re($# $
5ha@a8a%
2
-
5/26/2018 Project Brijesh Singh
53/133
UrmaB-%
*e!tam
7!u"
Duta"
t
C$#t!$;-
% F!$%art 7!u"1 00 0 / 2
/
-
5/26/2018 Project Brijesh Singh
54/133
Pe chart "h$;#( the "a!e" $ UrmaB-% # 5a#%h #a(ar area $ 5ha@a8a% &"--&" t"
c$m7ett$r
6
-
5/26/2018 Project Brijesh Singh
55/133
UrmaB-
%
*e!tam
7!u"
Duta"
t
C$#t!$;-
% F!$%art 7!u"
1 2 2 2 2
7e chart "h$;#( the "a!e" $ UrmaB-% # aa(ar area $ 5ha@a8a% &"--&"
t" c$m7ett$r
-
5/26/2018 Project Brijesh Singh
56/133
UrmaB-
%
*e!tam
7!u"
Duta"
t
C$#t!$;-
%
F!$%art
7!u"
+. 2 2 2
Pe chart "h$;#( the "a!e" $ UrmaB -% # Ma!;ara ch$;= area $ 5ha@a8a% &"--&" t"
c$m7ett$r
9
-
5/26/2018 Project Brijesh Singh
57/133
UrmaB-%
*e!tam
7!u"
Duta"
t
C$#t!$;-
% F!$%art 7!u"
+. + 2 2 2
7
-
5/26/2018 Project Brijesh Singh
58/133
7e chart "h$;#( the "a!e" $ urmaB-% # M$%#a(ar area $ 5ha@a8a% &"--&" t"
c$m7ett$r
=
-
5/26/2018 Project Brijesh Singh
59/133
UrmaB-%
*e!tam
7!u" Duta" t
C$#t!$;-
% F!$%art 7!u"
2 0 2 2 2
Pe chart "h$;#( the "a!e" $ UrmaB-% # m$ha# #a(ar area $ 5ha@a8a% &"--&" t"
c$m7ett$r
-
5/26/2018 Project Brijesh Singh
60/133
UrmaB-%
*e!tam
7!u" Duta" t
C$#t!$;-
% F!$%art 7!u"
1 / / +. 2
90
-
5/26/2018 Project Brijesh Singh
61/133
7e chart "h$;#( the "a!e" $ urmaB-% # Nehru #a(ar area $ 5ha@a8a% &"--&" t" c$m7ett$r
91
-
5/26/2018 Project Brijesh Singh
62/133
UrmaB-%
*e!tam
7!u"
Duta"
t
C$#t!$;-
% F!$%art 7!u"
2 0 2 2 2
Pe chart "h$;#( the "a!e" $ urmaB-% # O!% 8u" "ta#% area $ 5ha@a8a% &"--&" t"
c$m7ett$r
92
-
5/26/2018 Project Brijesh Singh
63/133
UrmaB-% *e!tam 7!u" Duta" t
C$#t!$;-
% F!$%art 7!u"
0 1 2 2 2
9/
-
5/26/2018 Project Brijesh Singh
64/133
7e chart "h$;#( the "a!e" $ urmaB-% # Pate! #a(ar area $ (ha@a8a% &"--&" t" c$m7ett$r
96
-
5/26/2018 Project Brijesh Singh
65/133
UrmaB-% *e!tam 7!u" Duta" t
C$#t!$;-
% F!$%art 7!u"
. 2 2 2 2
Pe chart "h$;#( the "a!e" $ urmaB-% # Prata7 &har area $ 5ha@a8a% &"--&" t" c$m7ett$r
9
-
5/26/2018 Project Brijesh Singh
66/133
UrmaB-
%
*e!tam
7!u"
Duta"
t
C$#t!$;-
%
F!$%art
7!u"
0 2 2 2 2
99
-
5/26/2018 Project Brijesh Singh
67/133
Pe chart "h$;#( the "a!e" $ urmaB-% # Ra> #a(ar area $ 5ha@a8a% &"--&" t"
c$m7ett$r
97
-
5/26/2018 Project Brijesh Singh
68/133
UrmaB-%
*e!tam
7!u" Duta" t
C$#t!$;-
% F!$%art 7!u"
/ 2 2 2 2
Pe chart "h$;#( the "a!e" $ UrmaB-% # Shah8a8a% area $ 5ha@a8a% &"--&" t"
c$m7ett$r
9=
-
5/26/2018 Project Brijesh Singh
69/133
UrmaB-%
*e!tam
7!u" Duta" t
C$#t!$;-
% F!$%art 7!u"
4 2 2 2 2
9
-
5/26/2018 Project Brijesh Singh
70/133
Pe chart "h$;#( the "a!e" $ urmaB-% # Sha"tr #a(ar area $ 5ha@a8a% &"--&" t"
c$m7ett$r
70
-
5/26/2018 Project Brijesh Singh
71/133
UrmaB-%
*e!tam
7!u" Duta" t
C$#t!$;-
% F!$%art 7!u"
+4 2 2 2 .
Pe chart "h$;#( the "a!e" $ UrmaB -% # *a"hu#%hara area $ 5ha@a8a% &"--&" t"
c$m7ett$r
71
-
5/26/2018 Project Brijesh Singh
72/133
UrmaB-%
*e!tam
7!u" Duta" t
C$#t!$;-
% F!$%art 7!u"
+ 2 2 2 2
72
-
5/26/2018 Project Brijesh Singh
73/133
Pe chart "h$;#( the "a!e" $ UrmaB-% # *>a9 #a(ar area $ 5ha@a8a% &"--&" t"
c$m7ett$r
7/
-
5/26/2018 Project Brijesh Singh
74/133
UrmaB-
% *e!tam 7!u"
C$#t!$;-
%
Duta"-
t F!$%art 7!u"
+42 42 + .
Pe chart "h$;#( the "a!e" $ UrmaB-% # 5ha@a8a% &"--&" t" c$m7ett$r
76
-
5/26/2018 Project Brijesh Singh
75/133
St$#-+ P$trate mac ct N$cu!
+/ 4 /
7
-
5/26/2018 Project Brijesh Singh
76/133
Pe chart "h$;#( the "a!e" $ St$#-+ # 5a#%h #a(ar area $ 5ha@a8a% &"--
&" t" c$m7ett$r
St$#-+ P$trate mac ct N$cu!
2 2 2 2 2
79
-
5/26/2018 Project Brijesh Singh
77/133
Pe chart "h$;#( the "a!e"$ St$#-+ # a& Na(ar area $ 5ha@a8a% &"--&" t"
c$m7ett$r
77
-
5/26/2018 Project Brijesh Singh
78/133
St$#-+ P$trate mac ct N$cu!
0 2 2 2 2
Pe chart "h$;#( the "a!e" $ St$#-+ # Ma!;ara ch$;= area $ 5ha@a8a% &"--&" t"
7=
-
5/26/2018 Project Brijesh Singh
79/133
C$m7ett$r
A!u"# F!$tra! A!$$
/ 2 2
7
-
5/26/2018 Project Brijesh Singh
80/133
Pe chart "h$;#( the "a!e" $ ALFUSIN # m$% #a(ar area $ 5ha@a8a% &"--&" t" c$m7ett$r
=0
-
5/26/2018 Project Brijesh Singh
81/133
A!u"# F!$tra! A!$$
. +0 2
Pe chart "h$;#( the "a!e" $ ALFUSIN # NEHRU Na(ar area $ 5ha@a8a% &"--&" t"
C$m7ett$r
=1
-
5/26/2018 Project Brijesh Singh
82/133
a"hu#%hara
Pate!
#a(ar
Ma!;ara
ch$;= aa(ar
Sha"tr
#a(ar
O!%
8u"
"ta#%
M$ha#
#a(ar
Shaha8a8a
%
Ra>
#a(a
r
5a#%h
#a(ar
Nehru
#a(ar
*>a9
#a(ar
Prata
7
&har
M$%
#a(ar
2 2 2 2 2 2 2 2 / / 2 2
=2
-
5/26/2018 Project Brijesh Singh
83/133
6ar chart "h$;#( the "a!e" $ A!u"#-% # &ar$u" area $ 5ha@a8a%
=/
-
5/26/2018 Project Brijesh Singh
84/133
A!u"#-
% A%ura
3 2
=6
-
5/26/2018 Project Brijesh Singh
85/133
Pe chart "h$;#( the "a!e" $ ALFUSIN # 5ha@a8a% &"--&" t" c$m7ett$r
A!u"#-% A%ura
/ 2
=
-
5/26/2018 Project Brijesh Singh
86/133
Pe chart "h$;#( the "a!e" $ ALFUSIN-D # 5a#%h #a(ar area $ 5ha@a8a% &"--&"
t" c$m7ett$r
=9
-
5/26/2018 Project Brijesh Singh
87/133
A!u"#-% A%ura
/ 2
Pe chart "h$;#( the "a!e" $ ALFUSIN-D # NEHRU #a(ar area $ 5ha@a8a% &"--&" t" c$m7ett$r
=7
-
5/26/2018 Project Brijesh Singh
88/133
*a"hu
#%har
a
Pate!
#a(a
r
Ma!;ara
ch$;=
a&
#a(ar
Sha"tr
#a(ar
O!%
8u"
"ta#%
M$ha
#
#a(ar
Shaha
8a8a%
Ra>
#a(a
r
5a#%h
#a(ar
Nehru
#a(ar
*>a9
#a(ar
Prata7
&har
M$%
#a(ar
2 2 2 2 2 2 2 2 2 4 4 2 2 2
==
-
5/26/2018 Project Brijesh Singh
89/133
6ar chart "h$;#( the "a!e" $ Ter$! !a # &ar$u" re($# $ 5ha@a8a%
=
-
5/26/2018 Project Brijesh Singh
90/133
Ter$! !a R$!et# T$r? "r
4 . 2
0
-
5/26/2018 Project Brijesh Singh
91/133
Pe chart "h$;#( the "a!e" $ TEROL LA # 5a#%h #a(ar area $ 5ha@a8a% &"--&" t" c$m7ett$r
Ter$! !a R$!et# T$r? "r2 2 3.
1
-
5/26/2018 Project Brijesh Singh
92/133
Pe Chart "h$;#( the "a!e" $ TEROL LA # Ma!;ara ch$;= area $ 5ha@a8a% &"--&" t" c$m7ett$r
2
-
5/26/2018 Project Brijesh Singh
93/133
Ter$! !a R$!et# T$r? "r
4 00 2
Pe chart "h$;#( the "a!e" $ TEROL LA # Nehru #a(ar area $ 5ha@a8a% &"--&" t" c$m7ett$r
/
-
5/26/2018 Project Brijesh Singh
94/133
Ter$! !a R$!te#
T$r?
"r
+/ 04 3.
6
-
5/26/2018 Project Brijesh Singh
95/133
Pe chart "h$;#( the "a!e" $ TEROL LA # 5ha@a8a% &"--&" t" c$m7ett$r
-
5/26/2018 Project Brijesh Singh
96/133
a"hu#%har Pate!
#a(ar
Ma!;ara
ch$;=
a&
#a(a
r
Sha"tr
#a(ar
O!% 8u"
"ta#%
M$ha#
#a(ar Shah8a8a%
Ra>
#a(ar
5a#%h
#a(ar
Nehru
#a(ar
*>a9
#a(a
r
Prata7
&har
M$%
#a(ar
2 2 2 2 2 2 2 2 2 . 2 2 /
9
-
5/26/2018 Project Brijesh Singh
97/133
6ar chart "h$;#( the "a!e" $ Ur&$% # Ar$u" re($# $
5ha@a8a%
Ur&$% Ur$t$#e
. 2
7
-
5/26/2018 Project Brijesh Singh
98/133
Pe chart "h$;#( the "a!e" $ 5a#%h Na(ar area $ 5ha@a8a% &"--&" t" c$m7ett$r
=
-
5/26/2018 Project Brijesh Singh
99/133
Ur&$% Ur$t$#e0 +
Pe chart "h$;#( the "a!e" $ URI*OID # M$%#a(ar area $ 5ha@a8a% &"--&" t"
c$m7ett$r
-
5/26/2018 Project Brijesh Singh
100/133
Ur&$% Ur$t$#e
+ 0
100
-
5/26/2018 Project Brijesh Singh
101/133
Pe chart "h$;#( the "a!e" $ URI*OID # Nehru #a(ar area $ 5ha@a8a% &"--&" t"
c$m7ett$r
101
-
5/26/2018 Project Brijesh Singh
102/133
Ur&$% Ur$t$#e
3
Pe chart "h$;#( the "a!e" $ URI*OID # 5ha@a8a% &"--&" t" c$m7ett$r
102
-
5/26/2018 Project Brijesh Singh
103/133
A!u"# F!$tra! A!$$
.3 +4
Pe chart "h$;#( the "a!e" $ ALFUSIN # N$%a &"--&" t" c$m7ett$r
10/
-
5/26/2018 Project Brijesh Singh
104/133
106
-
5/26/2018 Project Brijesh Singh
105/133
A!u"#-% A%ura
+ 2
Pe chart "h$;#( the "a!e" $ ALFUSIN -D # N$%a &"--&" t" c$m7ett$r
10
-
5/26/2018 Project Brijesh Singh
106/133
St$#-+ P$trate mac ct N$cu!
13 / +2+ / .
Pe chart "h$;#( the "a!e" $ STON-+ # N$%a &"--&" t" c$m7ett$r
109
-
5/26/2018 Project Brijesh Singh
107/133
ter$! !a R$!te# =mac =ct #$cu!
.0 / +2+ / .
107
-
5/26/2018 Project Brijesh Singh
108/133
Pe chart "h$;#( the "a!e" $ TEROL LA # N$%a &"--&" t" c$m7ett$r
10=
-
5/26/2018 Project Brijesh Singh
109/133
urimax $amflow contiflow
tamconti
n
velta
m
dyna
press
6/ 2 /06 6 /1 0
Pe chart "h$;#( the "a!e" $ URIMA # N$%a &"--&" t" c$m7ett$r
10
-
5/26/2018 Project Brijesh Singh
110/133
urimax;d veltam plus contiflow d dutas; t
19 / 12
110
-
5/26/2018 Project Brijesh Singh
111/133
Pe chart "h$;#( the "a!e" $ URIMA -D # N$%a &"--&" t" c$m7ett$r
111
-
5/26/2018 Project Brijesh Singh
112/133
urivoid urotone
9 2
Pe chart "h$;#( the "a!e" $ URI*OID # N$%a &"--&" t" c$m7ett$r
112
-
5/26/2018 Project Brijesh Singh
113/133
11/
-
5/26/2018 Project Brijesh Singh
114/133
RESULT AND
FINDIN5S
RESULTS AND FINDIN5S
116
-
5/26/2018 Project Brijesh Singh
115/133
?rimaxACiplaB is the maret leader in comparison to its
competitors and the maor competitors are 'yna press! oida mac is the maret leader.
#ur product $erol 4aACiplaB is least sold in comparison to its
competitors and the maret leaders are $orE sr and :oliten
respectively in *ha,ia-ad -ut the story is different in >oida where
$erol la is maret leader and :oliten is its competitor.
?rivoid ACiplaBis the maret leader in comparison to its competitor
and the maor competitor is ?rotone.
(lotral is the maret leader and our product )lfusinACiplaB is at the
second place in terms of sales.
)lfusin P'ACiplaB is maret leader and it has got no competitor as
such.
11
-
5/26/2018 Project Brijesh Singh
116/133
DOCTORS WHERE WE NEED TO PAY ATTENTION
DOCTOR NAME LOCATION
'r. ana :ohella rishna hospital
arinder +ohan
"ospital!+ohan
>agar
'r.>..oni *andhi >agar
'r.:avi praash harma *andhi >agar
'r.)shutosh mohan *andhi >agar
'r.aneev )garwal *andhi >agar
'r.'eepa sharma ratap
-
5/26/2018 Project Brijesh Singh
117/133
'r.agar
'r.)vdhesh $omar +odi >agar
ATTA SEC< +3NOIDAG
':. . )I8)4 "DICI)>
':. *?4)% *?$) "DICI)>
':. .C. ##' "DICI)>
':. )>@@*)4) "DICI)>
':. :)':) ?+): "DICI)>
':. ):' *):* "DICI)>
':.?4'@@ ")$:I "DICI)>
':. .'@8)4 *D)>)C#4#*I$
NITHARI SEC< +
':. . *?$) "DCI)> & ?:*@#>
': . :)+@" ?+): *@>@:)4 "DICI)>
':. .C. C")?'"):I *@>@:)4 "DICI)>
117
-
5/26/2018 Project Brijesh Singh
118/133
':.$.:. )4:) *@>@:)4 "DICI)>
':. +)>I"
':.*" *@>@:)4 &4@:#C#IC ?:*@#>
11=
-
5/26/2018 Project Brijesh Singh
119/133
LIMITATIONS
11
-
5/26/2018 Project Brijesh Singh
120/133
Lmtat$#" $ the "tu%9
1.>on cooperative -ehavior of the retailers.
2.>o response during pea hours.
/.'ata was very scattered so it was very difficult to conclude the result.
6.$hings are -ased on the retailers response so any false information may change the
result of the study.
.+edical representatives play a very vital role in the sales of medicines.
9.*ift and other pacage provided -y companies to the doctors encourage them to
prescri-e the particular -rand.
120
-
5/26/2018 Project Brijesh Singh
121/133
121
-
5/26/2018 Project Brijesh Singh
122/133
CONCLUSION
122
-
5/26/2018 Project Brijesh Singh
123/133
C$#c!u"$#
$his was the first time I was in maret so it was a great experience for me to wor a
great company lie cipla. during this proect I came to now how to convince other
12/
-
5/26/2018 Project Brijesh Singh
124/133
person and what is the ground reality of maret and how it is different from classroom
sessions.'uring this I also new a-out where the drugs are sold mostly and how
retailers play vital role in the sales of particular -rand of product on their counter and
how medical representative wors in the maret effectively and efficiently. )fter the
proect I come to now various players of the pharma industry and how it wors.Cipla
have maority of maret share in *ha,ia-ad and >oida in H?rological 'rugs. Cipla
is well nown -rand so it has got a very positive image in the minds of retailers and
consumers as well.
126
-
5/26/2018 Project Brijesh Singh
125/133
12
-
5/26/2018 Project Brijesh Singh
126/133
%I%4I#*:)"D
129
-
5/26/2018 Project Brijesh Singh
127/133
6I6ILIO5RAPHY
8e- itesG
www.iloveindia.com
www.google.com
%oosG
C.:.othari :esearch +ethodology
hilip otler +areting
127
http://www.iloveindia.com/http://www.google.com/http://www.iloveindia.com/http://www.google.com/ -
5/26/2018 Project Brijesh Singh
128/133
>ews paperG
$he @conomic $imes
12=
-
5/26/2018 Project Brijesh Singh
129/133
12
-
5/26/2018 Project Brijesh Singh
130/133
UESTIONAIRE
1/0
-
5/26/2018 Project Brijesh Singh
131/133
UESTIONAIRE
urvey for sales of cipla as compared to competitor
>ame of shop G
)rea
'ateG
1. '# you have urimaxAciplaBQ
AaByes A-B >o AcB>o stoc
2.Could you please tell me the sales of urimaxQ
/.which of the following -rands do you haveQ
AaB
-
5/26/2018 Project Brijesh Singh
132/133
AdB$amflow AeBContiflow AfB)ny other
6. Could you please tell me the sales of a-ove productsQ
.'# you have urimax;d AciplaQ
AaByes A-B >o AcB>o stoc
9.Could you please tell me the sales of urimax;dQ
7.which of the following -rands do you haveQ
AaB'utas t A-Bcontiflow d AcBveltam plus
AdB)ny other
=. Could you please tell me the sales of a-ove productsQ
.'o you have ston 1 AciplaQ
AaByes A-B >o AcB>o stoc
10.Could you please tell me the sales of ston 1Q
11.8hich of the following -rands you haveQ
AaBpotrate A-B mac AcBcit
AdBnoculi AeB)ny other
12. Could you please tell me the sales of a-ove productsQ
1/.'o you have )lfusin AciplaBQ
AaByes A-B >o AcB>o st
16.Could you please tell me the sales of )lfusinQ
1.8hich of the following -rands you haveQ
AaBflotral A-Balfoo AcB)ny other
1/2
-
5/26/2018 Project Brijesh Singh
133/133
19.Could you please tell me the sales of a-ove productsQ
17.'o you have )lfusin;d AciplaBQ
AaByes A-B >o AcB>o stoc
1=.Could you please tell me the sales of )lfusin;dQ
1.8hich of the following -rands you haveQ
AaBafdura A-B)ny other
20.Could you please tell me the sales of a-ove productsQ
21.'o you have urivoidAciplaBQ
AaByes A-B >o AcB>o stoc
22.Could you please tell me the sales of urivoidQ
2/.8hich of the following -rands you haveQ
AaBurotone A-B)ny other
26.Could you please tell me the sales of a-ove productsQ
2.'o you have terol laAciplaBQ
AaByes A-B >o AcB>o stoc
29.Could you please tell me the sales of terol laQ
27.8hich of the following -rands you haveQ
AaBroliten A-B)ny other
2=.Could you please tell me the sales of a-ove productsQ